EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer

Sagar Rayamajhi, Jared Sipes, Bidii Ngala, Amrita Mitra, Meizhang Li, Camille V Trinidad, Wei Cui, Mohammod Mahmudur Rahman, Foyez Ahmmed, Leonidas E Bantis, Mihaela E Sardiu, Dennis W Province und 2 weitere

Molecular & Cellular Proteomics · 2026-02 · 25 (2) · 101508

DOI: 10.1016/j.mcpro.2026.101508 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular & Cellular Proteomics, 2026-02. Verfasst von Sagar Rayamajhi und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Biomarkers, Tumor, Extracellular Vesicles, Early Detection of Cancer. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ovarian Cancer Research Fund Alliance, National Institutes of Health National Cancer Institute, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Small extracellular vesicles (sEVs), lipid-bilayer delimited particles (50-200 nm) released by cells, are emerging as a promising class of liquid biopsy biomarkers for elusive cancers, such as high-grade serous ovarian cancer (HGSOC). HGSOC originates from the fallopian tube (FT), progressing from p53 signatures to a precursor lesion known as serous tubal intraepithelial carcinoma (STIC). We hypothesize that sEVs contribute to ovarian cancer pathogenesis, carry cargo reflective of their site of origin, and serve as diagnostic biomarkers for early detection. To test this, we established a case-control cohort using archival plasma samples from 30 HGSOC patients (10 early stage [ES] and 20 late stage [LS]) and 40 healthy controls (HC). sEVs were enriched by size-exclusion chromatography and profiled by LC-MS/MS. Across all samples, 1078 EV-associated proteins (exoproteins) were identified, including 52 upregulated in ES HGSOC versus HC and 59 upregulated in LS HGSOC versus HCs (log2 fold change >1, p < 0.05). Upregulated EV proteins were prioritized based on FT origin and tissue expression in STIC lesions. Seven candidate biomarkers (MYL6, GSTP1, TTYH3, PRDX6, MUC1, MYH14, and PTGS1) were validated by immunohistochemistry in FT tissue harboring STIC lesions and in HGSOC tissues, as well as by Western blotting in FT/HGSOC cell-derived EVs. These findings suggest that circulating exoproteins upregulated in ES cancer disease reflect precursor lesions. A four-protein combinatorial panel (MUC1, MYL6, TTYH3, and GSTP1), selected using Akaike Information Criterion, yielded an area under the curve (AUC) of 0.975 and 90% sensitivity at 95% specificity for distinguishing ES HGSOC versus HC. In addition, increased MUC1 levels in circulating sEVs were confirmed by immunoassay (AUC = 0.840 for ES HGSOC versus HC; AUC = 0.860 for LS HGSOC versus HC, p < 0.05). In summary, our sEV proteomic analysis of ES HGSOC reveals exobiomarkers associated with early FT lesions, offering a promising avenue for detecting disease while it remains confined to the FT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsBiomarkers, TumorExtracellular VesiclesEarly Detection of CancerCystadenocarcinoma, SerousHumansFemaleCase-Control StudiesMiddle AgedProteomicsAgedNeoplasm GradingROC CurveTandem Mass Spectrometry

Stichwörter der Autor:innen

diagnostic biomarkerearly cancer detectionextracellular vesicleshigh-grade serous ovarian cancerliquid biopsy biomarkerproteomics

Substanzen

Biomarkers, Tumor

Autor:innen und Institutionen

  • Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA; Bioengineering Program, The University of Kansas, Lawrence, Kansas, USA.
  • Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA; Department of Biomedical Engineering, Vanderbilt University, Nashville, Tennessee, USA.
  • Department of Biostatistics and Data Science, University of Kansas Medical Center, Kansas City, Kansas, USA.
  • Department of Biochemistry and Microbiology, University of Arkansas for Medical Science, Little Rock, Arkansas, USA.
  • Department of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, Kansas, USA.

Förderung

  • Ovarian Cancer Research Fund Alliance
  • National Institutes of Health National Cancer Institute
  • National Institute of General Medical Sciences
  • Honorable Tina Brozman Foundation for Ovarian Cancer Research

Zitieren

APA

Rayamajhi, S., Sipes, J., Ngala, B., Mitra, A., Li, M., Trinidad, C. V., Cui, W., Rahman, M. M., Ahmmed, F., Bantis, L. E., Sardiu, M. E., Province, D. W., Pathak, H. B., & Godwin, A. K. (2026). Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer. Molecular & Cellular Proteomics, 25(2), 101508. https://doi.org/10.1016/j.mcpro.2026.101508

Vancouver

Rayamajhi S, Sipes J, Ngala B, Mitra A, Li M, Trinidad CV, et al. Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer. Molecular & Cellular Proteomics. 2026;25(2):101508. doi:10.1016/j.mcpro.2026.101508

BibTeX
@article{Rayamajhi2026,
  author = {Rayamajhi, Sagar and Sipes, Jared and Ngala, Bidii and Mitra, Amrita and Li, Meizhang and Trinidad, Camille V and Cui, Wei and Rahman, Mohammod Mahmudur and Ahmmed, Foyez and Bantis, Leonidas E and Sardiu, Mihaela E and Province, Dennis W and Pathak, Harsh B and Godwin, Andrew K},
  title = {Circulating Extracellular Vesicle Protein Biomarkers for the Early Detection of High-Grade Serous Ovarian Cancer},
  journal = {Molecular & Cellular Proteomics},
  year = {2026},
  volume = {25},
  number = {2},
  pages = {101508},
  doi = {10.1016/j.mcpro.2026.101508}
}
Kostenlos starten →